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Voriconazole versus Liposomal Amphotericin B 









a trial of voriconazole, as compared with liposomal am-
photericin B, for patients with neutropenia and persist-





 leave many questions about what the trial actually
demonstrated and how the findings should be applied. The
abstract implies that the study showed equivalence and con-
cludes, “Voriconazole is a suitable alternative to amphoter-
icin B preparations.” Yet the text and the accompanying ed-
itorial point out that the prespecified statistical criterion for
equivalence was not met. To confuse the issue further, cor-
respondents from the Food and Drug Administration pro-
vide alternative data, indicating that voriconazole was actually
statistically inferior to liposomal amphotericin B with respect




 Thus, whether the study showed
equivalence, near equivalence, or frank inferiority remains
unclear.
Even if equivalence had been demonstrated, the clinical
implications of the findings would remain uncertain. Thera-
peutic decision making must take into account not just effi-




 but also cost.
Avoidance of toxic effects may allow a net cost savings de-
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 The trial by Walsh et al., which compared
voriconazole with liposomal amphotericin B for the empiri-
cal treatment of neutropenic fever, presents a dilemma in
conducting this type of study. Major goals in the empirical
treatment of neutropenic fever include survival, deferves-
cence, and the prevention of infections. Whether this com-
posite end point is appropriate for the evaluation of an anti-
fungal drug remains controversial. A previous trial reported
by Walsh et al. underscores this problem. Numerous un-
known additional variables in both studies probably account
for the difference in the efficacy rates for liposomal ampho-
tericin B despite a similar study design (effective in 129 of
422 patients [30.6 percent] in the current trial vs. 172 of




 In our opinion, the
main end points for this type of trial should focus only on
the prevention of fungal infections, survival, and tolerance
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 Walsh et al. used a composite scoring system





failed to point out or explain why the rate of response to
liposomal amphotericin B in their study (30.6 percent) was
much lower than the rates in previous studies in patients





nazole, voriconazole is metabolized by hepatic P-450 cyto-




Patients at risk for invasive fungal infections tend to receive
multiple medications that could potentially interact with
these cytochrome enzymes. Since the authors did not men-
tion that patients with drug interactions were excluded from
their study, we wonder whether the lower response rates in
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 The overall response rate that Apisarntha-
narak and colleagues cite is measured by a set of criteria
that were formulated in 1994 and used in a study comparing










the resolution of fever as one of these criteria for a response
in recognition of the time-honored use of this end point in
previous studies of antibacterial and antifungal treatment in
patients with febrile neutropenia. However, we have learned
over time that although fever in this setting is a valuable
marker for the risk of infection, the resolution of fever is not
necessarily a reliable marker for a therapeutic response.
In the current study, patients were prospectively stratified
as being at high or moderate risk of infection. The moderate-
risk group included patients who received the study drug for
a relatively short period. In our earlier study, the median pe-





as in the current study, it was 7.0 days. A shorter period of
treatment with the study drug allowed less time for the fever
to resolve before recovery from neutropenia. This lower rate
of defervescence resulted in a lower overall response rate in
both groups. We included the resolution of fever as a crite-
rion for success. However, if one removes this criterion, the
overall response rate is substantially higher in both groups,
and the 95 percent confidence intervals demonstrate non-
inferiority (Table 1). The lower response rates in the current
study were not related to plasma voriconazole concentra-
tions, which were higher than the minimal inhibitory con-
centrations for most medically important fungal pathogens.
We concur with Ullmann et al. that the main end points
for future trials of antifungal agents should exclude the res-
olution of fever and focus on the prevention of breakthrough
invasive fungal infections, survival (in cases of invasive my-
cosis), and the response to treatment of base-line fungal in-
fections. Fever can be assessed separately as a secondary end
point.
In response to Dr. Johnson: our noninferiority trial of
voriconazole as compared with liposomal amphotericin B
demonstrated that the lower limit of the 95 percent con-
fidence interval for the point estimate falls just outside the
lower limit of ¡10 percentage points specified by the pro-
tocol (95 percent confidence interval, ¡10.6 to 1.6 percent-
age points). The point estimate and 95 percent confidence
interval are presented in the abstract and text of our report.
Examination of the individual elements of the composite
score for success indicates that the two treatments are similar,
with the prospectively defined stratum of high-risk patients
having the greater benefit (95 percent confidence interval,
¡9.0 to 12.4 percentage points). In addition, voriconazole
was superior in reducing documented breakthrough fungal
infections, particularly in the high-risk cohort.
With regard to the type of analysis performed, the pro-
spectively developed and approved statistical plan of the
National Institute of Allergy and Infectious Diseases My-
coses Study Group was based on a primary analysis of raw
 




















































































































































Fever included 26 31 ¡4.5 (¡10.6 to +1.6)
Fever excluded 82 85 ¡2.3 (¡7.7 to +2.3)
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data. The corporate sponsor submitted a primary stratified
analysis and a secondary analysis of raw data. With regard to
the issue of cost effectiveness, a prospective analysis of re-
source utilization in the current study demonstrated a sig-
nificant reduction in the number of hospital days among
high-risk patients treated with oral voriconazole, suggest-
ing potentially important cost savings. Pharmacoeconomic
studies should be performed once the acquisition cost per
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 report the ef-
ficacy of high-dose intravenous immune globulin for the
treatment of stiff-person syndrome. Stiff-person syndrome
is a devastating disorder, and evidence of the associated im-





the next decade, it was confirmed that stiff-person syndrome
was caused, in particular, by damage by an autoimmune
mechanism.
Intravenous immune globulin is extraordinarily costly;
thus, the current focus of interest among clinicians is not on
the efficacy of this approach but, rather, on the timing of the
treatment and its long-term outcome, including the duration
of the effect and any adverse consequences. Dalakas et al.
failed to address this issue, because they terminated their
comparative observation one month after the end of the
double-blind study, even though in the group that received
immune globulin first, titers of antibodies against glutamic
acid decarboxylase (GAD65) had increased significantly four
months after the completion of the study, whereas in the
group given placebo first, the titers were monitored for only
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Piccolo G, Cosi V, Zandrini C, Moglia A. Steroid-responsive and de-
pendent stiff-man syndrome: a clinical and electrophysiological study of 
two cases. Ital J Neurol Sci 1988;9:559-66.
 
To the Editor: 
 
Dalakas et al. report the efficacy of intra-
venous immune globulin for treating stiff-person syndrome.
They did not report whether cerebrospinal fluid was ana-
lyzed in order to determine whether anti-GAD65 antibodies
were being synthesized intrathecally. As shown recently by




 the production of antibod-
ies within the central nervous system seems to have an im-
portant role in the pathogenesis of the disorder, by affecting









 within the central nervous system. Immune glob-
ulin should work in the periphery, since its hypothesized
mechanism of action is to reduce the levels of circulating
antibody against an antigen target that accelerates IgG catab-
olism or to induce an anti-idiotypic antibody response. Does
the activity in the periphery reflect what is happening in the
cerebrospinal fluid?
Dalakas et al. also report that the reduction in anti-
GAD65 antibody titers after immune globulin therapy did
not correlate with the degree of clinical improvement. Can
we suppose that a correlation exists between the clinical out-
come and the level of the antibodies in cerebrospinal fluid
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Dinkel K, Meinck HM, Jury KM, Karges W, Richter W. Inhibition of 
gamma-aminobutyric acid synthesis by glutamic acid decarboxylase auto-






 Contrary to the contentions of Sudo et al.,
the main concern of clinicians caring for patients with
stiff-person syndrome is not when to treat but how best
to treat the disease; hence, the need for controlled studies to
determine the efficacy of the various proposed therapies. My
colleagues and I demonstrated that intravenous immune
globulin improves or reverses even the long-standing dis-
abling symptoms in most patients with stiff-person syn-
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drome. Furthermore, we monitored the anti-GAD65 an-
tibody titers not for one month, as Sudo et al. suggest, but
for up to three months. Immune globulin is an immuno-
modulating (not an immunosuppressive) agent that modifies
but does not permanently suppress various immune factors.
Consequently, the rebound in the antibody titers after the
end of treatment is not unexpected. Although the purpose
of our study was to establish the efficacy of immune glob-
ulin and not to assess its long-term effectiveness, we report-
ed long-term follow-up data that were collected for at least
two years after the completion of the study.
Dr. Solaro refers to our previous study of the intrathecal
synthesis of IgG antibodies1 and wonders whether immune
globulin acts in the periphery or directly within the central
nervous system to suppress antibody production. This per-
tinent question also relates to the pathogenic role of anti-
GAD65 antibodies. GAD65 is a cytoplasmic antigen that
may not be easily recognized by the immune system, and the
antibody titers do not correlate with disease severity. Thus,
the relation between the suppression of anti-GAD65 anti-
body titers and the magnitude of clinical benefit after im-
mune globulin therapy is unclear. Immune globulin probably
suppresses anti-GAD65 antibodies in the periphery through
an idiotypic–anti-idiotypic interaction.2,3 However, the IgG
molecules within the immune globulin cross the blood–cer-
ebrospinal fluid barrier4 and may enter the brain; whether
they also exert an effect in situ is unknown. Although high
titers of anti-GAD65 antibodies in serum and cerebrospi-
nal fluid are highly specific for stiff-person syndrome, an-
other target antigen or surface receptor, in conjunction with
GAD65, may be more directly involved in GABAergic trans-
mission and may correlate better with the severity of symp-
toms. Our search for other target antigens in affected patients
continues.
MARINOS C. DALAKAS, M.D.
National Institutes of Health
Bethesda, MD 20892-1382
dalakasm@ninds.nih.gov
1. Dalakas MC, Li M, Fujii M, Jacobowitz DM. Stiff person syndrome: 
quantification, specificity, and intrathecal synthesis of GAD65 antibodies. 
Neurology 2001;57:780-4.
2. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and 
inflammatory diseases with intravenous immune globulin. N Engl J Med 
2001;345:747-55.
3. Dalakas MC. Intravenous immunoglobulin in the treatment of autoim-
mune neuromuscular diseases: present status and practical therapeutic 
guidelines. Muscle Nerve 1999;22:1479-97.
4. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with 
high-dose intravenous immunoglobulin therapy: frequency and risk factors. 
Ann Intern Med 1994;121:259-62.
Octreotide for Tumor-Induced Osteomalacia
To the Editor: Seufert et al. (Dec. 27 issue)1 describe a
man with tumor-induced (oncogenic) osteomalacia, in which
the subcutaneous administration of octreotide abolished re-
nal tubular phosphate wasting. The authors suggest that in
patients who cannot undergo surgery, phosphate wasting
may be relieved by treatment with somatostatin analogues,
provided that the tumor expresses somatostatin receptors.
We believe that this statement is a misleading generaliza-
tion. We observed a case of oncogenic osteomalacia in which
total-body octreotide scintigraphy detected the tumor. We
therefore intravenously administered octreotide at a dose
Figure 1. Serum Phosphorus Level and Threshold for Renal Tubular Reabsorption of Phosphate during
Intravenous Octreotide Therapy in a Patient with Tumor-Induced Osteomalacia.
The normal range for the serum phosphorus level is 0.8 to 1.4 mmol per liter; the normal range for the
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of 600 µg per day for six days — a dose in the same order
of magnitude as the dose administered subcutaneously by
Seufert et al. We did not observe any effect on the biochem-
ical variables (Fig. 1).
The lack of response in our patient could be attributed ei-
ther to the heterogeneous distribution of somatostatin re-
ceptors among tumor cells2,3 or to the prevalence of cells
lacking somatostatin receptors, as has been documented in
some neuroendocrine tumors.3 In the latter case, it is pos-
sible that treatment with the analogues of somatostatin af-
fects only some areas of the tumor. In fact, octreotide binds
with high affinity to somatostatin receptor subtypes 2 and
5 and with moderate affinity to subtype 3 but does not
bind to subtypes 1 and 4. Finally, it is unclear whether the
secretion of phosphaturic factors by the tumor cells is mod-
ulated by somatostatin receptors. In any case, we do not sup-
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00193 Rome, Italy
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1. Seufert J, Ebert K, Müller J, et al. Octreotide therapy for tumor-induced 
osteomalacia. N Engl J Med 2001;345:1883-8.
2. Wynick D, Anderson JV, Williams SJ, Bloom SR. Resistance to meta-
static pancreatic endocrine tumours after long-term treatment with the so-
matostatin analogue octreotide (SMS 201-995). Clin Endocrinol (Oxf ) 
1989;30:385-8.
3. Lamberts SWJ, van der Lely A-J, de Herrder WW, Hofland LJ. Octre-
otide. N Engl J Med 1996;334:246-54.
The authors reply:
To the Editor: Paglia et al. point out that octreotide ther-
apy does not affect phosphate wasting in all patients with
tumor-induced osteomalacia. We have become aware of sim-
ilar cases characterized by the obvious contradiction of pos-
itive results on octreotide scintigraphy and little therapeutic
effect of the compound. By reporting our single case, we
certainly did not mean to imply that the findings could be
generalized to all tumors. The two findings we wanted to
stress are that tumors can be diagnosed with the use of oc-
treotide scans if conventional localization procedures fail and
that a therapeutic trial of octreotide may be worthwhile in
individual patients. Furthermore, this case might be consid-
ered as a paradigm for the novel concept of secretory control
of phosphaturic substances in humans. We notice differences
between the two patients such as the route of octreotide ad-
ministration and the basal phosphate reabsorption thresh-
old — differences that can be evaluated only if one has the
opportunity to analyze more patients. However, fibroblast
growth factor 23 was recently reported to suppress 25-
hydroxyvitamin D3 1a-hydroxylase activity in the kidney,
1
which may, in part, explain the low levels of 1,25-dihydrox-
yvitamin D3 in patients with tumor-induced osteomalacia.
2
This finding could contribute to the low renal tubular
threshold of phosphate reabsorption. Concomitant 1,25-
dihydroxyvitamin D3 treatment in our patient may have had
a permissive effect on normalization of phosphaturia. The
relative heterogeneity of underlying histologic entities3,4 may
serve as an alternative explanation for the lack of an effect of
octreotide in octreotide-positive tumors. Although tumor-
induced osteomalacia is a rare disorder, we propose that sys-
tematic analysis of somatostatin-receptor expression has rel-
evance to tumor-derived phosphatonin secretion.
In Table 1 of our article, the threshold for renal tubular
reabsorption of phosphate before octreotide therapy should






1. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of 
FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl 
Acad Sci U S A 2001;98:6500-5.
2. Strewler GJ. FGF23, hypophosphatemia, and rickets: has phosphatonin 
been found? Proc Natl Acad Sci U S A 2001;98:5945-6.
3. Crouzet J, Mimoune H, Beraneck L, Juan LH. Hypophosphatemic os-
teomalacia with plantar neurilemoma: a review of the literature (100 cases). 
Rev Rhum Engl Ed 1995;62:463-6.
4. Park YK, Unni KK, Beabout JW, Hodgson SF. Oncogenic osteomala-
cia: a clinicopathologic study of 17 bone lesions. J Korean Med Sci 1994;
9:289-98.
Childhood Infections and Autoimmune Diseases
To the Editor: The article by Zinkernagel (Nov. 1 issue)1
and the accompanying editorial2 discuss the attractive and
popular notion that the occurrence of fewer infectious dis-
eases during childhood leads to an increase in the incidence
of autoimmune diseases. This idea, however, is not soundly
based. The apparently increased incidence of autoimmune
diseases in industrialized countries may well be attributable
to the use of improved diagnostic tools and widespread
awareness of these diseases. Large-scale epidemiologic stud-
ies have been done only with regard to type 1 diabetes.
Moreover, there is evidence that the prevalence of autoim-
mune diseases in underdeveloped countries is much higher
than previously suspected.3 This would be in keeping with
the findings in Sardinia, which has the highest prevalence
of autoimmune diseases in Europe (similar to that in Fin-
land), despite having, until recently, a high incidence of in-
fectious diseases.4 Finally, the idea that coxsackievirus B can
lead to type 1 diabetes is unproved, and the proposal that
molecular mimicry (i.e., the presence of viral antigenic deter-
minants that resemble those of the host) may explain the






1. Zinkernagel RM. Maternal antibodies, childhood infections, and auto-
immune diseases. N Engl J Med 2001;345:1331-5.
2. Rosen FS, Mackay I. The immunology series comes to an end. N Engl 
J Med 2001;345:1343-4.
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3. Molokhia M, McKeigue PM, Cuadrado M, Hughes G. Systemic lupus 
erythematosus in migrants from West Africa compared with Afro-Caribbe-
an people in the UK. Lancet 2001;357:1414-5.
4. Stroffolini T, Franco E, Mura I, et al. Age-specific prevalence of hepa-
titis A virus infection among teenagers in Sardinia. Microbiologica 1991;
14:21-4.
5. Cainelli F, Manzaroli D, Renzini C, Casali F, Concia E, Vento S. Cox-
sackie B virus-induced autoimmunity to GAD does not lead to type 1 di-
abetes. Diabetes Care 2000;23:1021-2.
To the Editor: Zinkernagel describes the function of ma-
ternal antibodies as passive protective mediators that help to
generate immunity to invading microbes during early on-
togeny. We believe that his view neglects a large body of
evidence demonstrating that maternal antibodies also exert
a variety of active stimulatory functions on the nascent im-
mune system of the newborn.1,2 Maternal antibodies stim-
ulate T-cell–dependent idiotypic responses that have long-
term effects, and they are involved in the establishment of
the T-cell repertoire. In addition, in animals, they may sub-
stantially enhance immune responses and can transfer a car-
rier sensitivity (a T-cell–dependent function) from mothers
to offspring. In mice, maternal immunization with antigen
or anti-idiotypic antibodies induces the production of an-
tigen-reactive IgM antibodies in nonimmunized first-gen-
eration offspring. A further argument against the view that
maternal antibodies provide only passive protection is the
fact that even antibodies that do not react with the antigen
— namely, anti-idiotypes — are able to transfer antimicro-
bial protection from mothers to offspring. Finally, maternally
derived IgG antibodies induce long-lasting, allergen-specific
suppression of IgE responsiveness in offspring. 
We believe that maternal antibodies indeed exert a variety
of important active stimulatory functions. These depend on
idiotypic interactions among B and T cells, which thus form
a physiologically active idiotypic network.3,4
HILMAR LEMKE, PH.D.
HANS LANGE, PH.D.
Christian Albrechts University at Kiel
D-24098 Kiel, Germany
hlemke@biochem.uni-kiel.de
1. Lemke H, Lange H. Is there a maternally induced immunological im-
printing phase à la Konrad Lorenz? Scand J Immunol 1999;50:348-54.
2. Idem. Generalization of single immunological experiences by idiotypi-
cally mediated clonal connections. Adv Immunol (in press).
3. Jerne NK. The Nobel Lectures in Immunology: the Nobel prize for 
physiology or medicine, 1984: the generative grammar of the immune sys-
tem. Scand J Immunol 1993;38:1-9.
4. Janeway CA Jr. How the immune system works to protect the host from 
infection: a personal view. Proc Natl Acad Sci U S A 2001;98:7461-8.
Dr. Zinkernagel replies:
To the Editor: My article is not comprehensive, and there
are many host and environmental factors that influence au-
toimmune disease.1 Better epidemiologic data in different
human populations would clearly be very valuable. I do not
want to push the notion that infants with fewer infections
have a higher incidence of autoimmune disease than other
infants; rather, I would like to argue that infants with insuf-
ficient maternally transmitted immunoglobulins, or “clean
kids,” either are not sufficiently protected or become infect-
ed too late to benefit from maternal antibody protection.
I propose that the transfer of maternal antibodies offers a
mechanism for “natural,” or “physiologic,” vaccination by
attenuating early infections in infants. This mechanism bal-
ances decreasing passive maternal protection with active
infection and with the maturing immune system of the baby.
It explains why vertebrates transfer antibodies to offspring
and why emerging infections are generally more severe in
the first few generations of new hosts than in subsequent
generations.
I agree that mimicry, though possible, is rare and that in
many cases, this possibility is supported only by poorly spe-
cific assays in vitro. Therefore, the overall role of mimicry in
autoimmune disease remains elusive.2 HLA–disease associ-
ations have been observed particularly frequently in patients
with autoimmunity, which may indicate that chronic or
subclinical infections can induce autoimmune disease, even
though they are often not recognized as triggering events.3
I propose that during the phase of protection provided by
maternal antibodies, favorable, physiologic immunizations
of offspring limit early infections, including those that even-
tually lead to chronic immunopathologic conditions (or au-
toimmunities). Factors such as increased hygiene and the
absence of breast-feeding or the use of breast-feeding for
short periods influence the time and dose kinetics of some
infections unfavorably, shifting them toward autoimmunity.
Such shifts may also be found in developing countries; the
increase in the incidence of diabetes in adults between 20
and 40 years of age in southern India is perhaps an example.4
In theory, the postulated active effects of maternal anti-
bodies on the immune system of the offspring by way of
idiotypic networks cannot be ruled out. But I am unaware
of solid evidence of a survival advantage or disadvantage
with respect to infections or autoimmune diseases. Although
anti-idiotypic responses may be demonstrated in selected
experimental or clinical conditions,5 such evidence does not
prove that idiotypic networks have active regulatory roles,
either in general or as a result of the influence of maternal
antibodies on B-cell or T-cell responses of the offspring.
Examination of the cited references suggests that these ef-
fects are probably dwarfed in importance by the evolution-
ary selection pressures exerted by infections that kill off-
spring early.




1. Bach JF. Protective role of infections and vaccinations on autoimmune 
diseases. J Autoimmun 2001;16:347-53.
2. Benoist C, Mathis D. Autoimmunity provoked by infection: how good 
is the case for T cell epitope mimicry? Nat Immunol 2001;2:797-801.
3. Haddad J, Deny P, Munz-Gotheil C, et al. Lymphocytic sialadenitis of 
Sjogren’s syndrome associated with chronic hepatitis C virus liver disease. 
Lancet 1992;339:321-3.
4. Ramachandran A, Snehalatha C, Kapur A, et al. High prevalence of di-
abetes and impaired glucose tolerance in India: National Urban Diabetes 
Survey. Diabetologia 2001;44:1094-101.
5. Levy R, Miller RA. Therapy of lymphoma directed at idiotypes. In: The 
lymphomas: current concepts in pathogenesis and management. Journal of 
the National Cancer Institute monographs. No. 10. Bethesda, Md.: Na-
tional Cancer Institute, 1990:61-8. (NIH publication no. 90-1930.)
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Case 1-2002: Loa loa
To the Editor: The case discussion by Nutman and Kradin
(Jan. 10 issue)1 triggered the recollection of a case of Loa
loa infection that I saw years ago as a Peace Corps physi-
cian in Cameroon, West Africa. A healthy young man not-
ed migratory arthralgia of the joints. He had few, if any,
constitutional symptoms. One wrist was red, warm, and
swollen but fully mobile and mildly tender. We diagnosed
infection with L. loa and began treatment with diethylcar-
bamazine. 
Some weeks later, he reappeared with two gracile white
worms preserved in ethanol. He reported that after a day
or so of therapy, the worms had crawled out of his anterior
chest wall. Being resourceful and unflappable, he preserved
them and brought them in for identification. The worms
were sent to the Centers for Disease Control, which con-
firmed that there was one male and one female L. loa.
The cause-and-effect response to therapy was so dramatic
and striking that the case remains unforgettable decades
later. Would that all our patients’ infestations so definitively
and resolutely declared their response to our ministrations.
One teaching point that was not mentioned in the case re-
port is that this predilection of the worm to get out when
challenged is the basis for the admonition not to treat pa-
tients when the worm makes its classic traversal of the sclera.
HENRY GREENBERG, M.D.
St. Luke’s–Roosevelt Hospital Center
New York, NY 10019
hmg1@columbia.edu
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Dr. Nutman replies:
To the Editor: Dr. Greenberg emphasizes several salient
and often dramatic clinical features of loiasis in long-term
visitors to (or temporary residents of ) regions of the world
where L. loa is endemic: Calabar swellings, the subconjunc-
tival migration of the adult parasite (eye worm), and the
appearance of adult worms after treatment with diethylcar-
bamazine. In our experience, however, the parasites rarely
emerge from the skin spontaneously after treatment but,
rather, are found as subcutaneous papular or vermiform
eruptions. When these eruptions are examined by biopsy1
or nicked with a scalpel while the patient is under local an-
esthesia, adult L. loa worms are found. Indeed, my colleagues
and I found, in our initial study of 20 temporary residents
of West and Central Africa with loiasis,2 many of whom were
Peace Corps volunteers, that 13 (65 percent) had such a
finding after the administration of diethylcarbamazine, typ-
ically within the first 48 hours.
When access to ophthalmologic services is available, the
adult L. loa worm can be removed during its subconjunc-
tival migration, thus allowing the definitive diagnosis of
loiasis to be made. Because of the velocity of the worm, ex-
traction is not very common, and it is unusual to have the
administration of diethylcarbamazine coincide with the pres-
ence of a worm under the conjunctiva. Moreover, to my
knowledge, emergence of adult worms through the conjunc-
tiva after therapy with diethylcarbamazine has not been re-
ported. The real concern with treatment is the precipitation
of severe, life-threatening adverse reactions, such as enceph-
alitis or encephalopathy, which can occur in patients with
increased parasite burdens (high-grade microfilaremia).3 Al-
though apheresis to reduce microfilarial burdens,4 graded
diethylcarbamazine dosing schedules, and concomitant ad-
ministration of corticosteroids have been used successfully
to prevent some of the serious post-treatment reactions, in
heavily infected patients — particularly in West and Cen-
tral Africa — there are few treatment options. Fortunately
for the traveler or temporary resident who acquires loiasis,
parasite burdens are low, and severe post-treatment reactions,
though dramatic, are infrequently a cause for concern.
THOMAS B. NUTMAN, M.D.
National Institutes of Health
Bethesda, MD 20892-0425
tnutman@niaid.nih.gov
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Case 4-2002: Cancer-Associated Obstruction 
and Glomerular Damage
To the Editor: Case 4-2002 (Jan. 31 issue) described a
75-year-old man with acute renal failure five months after
cystoprostatectomy and urethrectomy for carcinoma.1 Re-
cently, we cared for a 52-year-old woman who had acute
renal failure after surgery for an obstructing transitional-
cell carcinoma of the bladder. The follow-up serum creat-
inine concentration was 1.5 mg per deciliter. Two months
after surgery, she presented with acute oliguric renal failure.
No obstruction was present, and hemodialysis was initiated.
Findings on a biopsy of the kidney were consistent with the
presence of anti–glomerular basement membrane antibody
disease: light microscopy revealed an acute necrotizing, cres-
centic glomerulonephritis, and immunofluorescence was
strongly positive for linear deposition of IgG in the glomer-
ular basement membrane. Hemoptysis later developed, and
treatment with plasmapheresis, corticosteroids, and cyclo-
phosphamide was begun. The titer of anti–glomerular base-
ment membrane was 191 U per milliliter before therapy, as
assessed by enzyme-linked immunosorbent assay. Hemop-
tysis resolved, but there was no recovery of renal function.
These case reports suggest that obstructions associated
with cancer may result in glomerular damage, triggering
anti–glomerular basement membrane disease. Of interest in
this regard are three reports of patients in whom anti–glo-
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merular basement membrane disease developed after lith-
otripsy.2-4
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Vaccination with HPV-18 E7–Pulsed 
Dendritic Cells in a Patient with Metastatic 
Cervical Cancer
To the Editor: The management of disseminated carcinoma
of the cervix that is no longer amenable to control with
surgery or radiation therapy has not improved significantly
with the advent of modern chemotherapy. The one-year
survival rate remains between 10 percent and 15 percent.1
Studies have provided a rationale for using dendritic cells
as natural adjuvants for human immunotherapy.2-4 
We describe a 52-year-old woman with multiple lung
metastases secondary to recurrent human papillomavirus
type 18 (HPV-18)–associated adenocarcinoma of the uter-
ine cervix. In 1997 she underwent external irradiation and
intracavitary brachytherapy combined with weekly intrave-
nous infusions of cisplatin and followed by an adjunctive
hysterectomy for stage IB2, grade III, cervical cancer. The
patient did well until January 2000, when a chest x-ray film
Figure 1. Immunologic and Histologic Findings in a Woman with Metastatic Cervical Cancer.
Delayed-hypersensitivity skin tests were performed at the time of the third vaccination with HPV-18
E7–pulsed dendritic cells. HPV-18 E7 antigen induced an erythematous reaction with induration (Panel A).
Large tumor cells were clearly evident in biopsy specimens of the primary lesion obtained before vac-
cination (Panel B; hematoxylin and eosin, ¬400). After 10 months of treatment, examination of bron-
choscopic-biopsy tissue revealed a predominant mononuclear-cell infiltrate in the pulmonary cavitary
lesion (Panel C; hematoxylin and eosin, ¬600). The presence of macrophages was confirmed by im-
munohistochemical staining for CD68 (KP-1), whereas there was no staining for epithelial-cell cytokeratin
or tumor-associated mucin (not shown). Twenty months after the initiation of vaccine treatment, re-
current adenocarcinoma was evident in a bronchoscopic-biopsy specimen (Panel D; hematoxylin and
eosin, ¬400).
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and computed tomographic (CT) scans revealed metastatic
lesions in both lungs and bilateral pleural effusions.
To inhibit tumor progression, we subcutaneously admin-
istered autologous mature, monocyte-derived dendritic cells
pulsed with HPV-18 E7 oncoprotein. The first five injec-
tions were given at intervals of 10 to 14 days (3 million to
5 million dendritic cells per injection). To increase the num-
ber of T cells potentially responsive to disease, the first, sec-
ond, and fourth vaccinations were followed 72 hours later
by the adoptive transfer of autologous T cells (1.5¬107 cells)
that had been stimulated in vitro with HPV-18 E7–pulsed
dendritic cells. Low-dose interleukin-2 (1 million U per
square meter of body-surface area per day for three days, in-
fused over a six-hour period) was concomitantly adminis-
tered. Vaccinations 6 to 14 were administered at intervals of
30 to 60 days. 
The patient had minor side effects, including tender in-
duration at the site of the injections and an influenza-like
syndrome at the time of interleukin-2 infusion. After the
third vaccination, we assessed whether delayed hypersensitiv-
ity had occurred by intradermally injecting the patient with
HPV-18 E7 oncoprotein (Fig. 1A) or lethally irradiated au-
tologous tumor cells. There was swelling and induration,
indicating a strong local reaction to the HPV antigen and tu-
mor cells. A skin biopsy of both injection sites, used to as-
sess whether delayed-type hypersensitivity had occurred, re-
vealed marked CD4+ and CD8+ T-cell infiltration. Serial
CT scans showed no evidence of tumor progression during
13 months of therapy. Cavities developed in the majority
of lesions. In contrast to results obtained before vaccination
(Fig. 1B), after 10 months of treatment, CT-guided fine-
needle biopsy revealed fibrosis and macrophage infiltration
but no viable tumor cells (Fig. 1C).
After the initiation of dendritic-cell immunotherapy, the
patient resumed her normal activities. Twenty months later,
she became short of breath. CT showed that her pulmonary
masses had increased in size. Bronchoscopic biopsy con-
firmed that metastatic disease had recurred (Fig. 1D). De-
layed-hypersensitivity status against HPV-18 E7 oncoprotein
was not reassessed at this time. The patient died 23 months
after the beginning of the dendritic-cell immunotherapy.
Although this approach did not result in permanent remis-
sion, it inhibited disease progression and markedly improved
the patient’s performance status for an extended period with-
out clinically significant adverse effects.
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Acute Dystonic Reactions to “Street Xanax”
To the Editor: Acute dystonic reactions have been reported
after the ingestion of numerous medications that alter do-
paminergic tone in the basal ganglia or antagonize dopamine
D2 receptors. At the emergency department of an urban
community hospital, we have recently treated six patients
presenting with acute dystonia. All patients reported the in-
gestion of what street sellers had assured them was Xanax
(alprazolam). In five of these patients, the ingested drug
was actually proved to be haloperidol.
Three teenage boys presented to the emergency depart-
ment with symptoms consistent with torticollis, oculogyric
crisis, and opisthotonos. Each reported the ingestion of “one
or two” tablets of “Xanax” 12 to 16 hours before admis-
sion. Two of these patients specifically described blue tab-
lets bearing the inscription “GG126,” and the third supplied
an unused pill with the same markings. The drugs were iden-
tified as 10-mg tablets of the Geneva brand of generic halo-
peridol. All three patients had rapid resolution of their
symptoms after the administration of intravenous diphen-
hydramine.
We also treated three additional patients with more sub-
tle clinical presentations. A child presented with intermit-
tent mouth puckering and sedation, followed by torticollis
and involuntary tongue movements. A 32-year-old woman
presented with mild, intermittent bruxism. And a teenage
boy presented with a feeling of weakness and spasm in his
back and a sensation of swelling in his tongue, followed by
dysarthria, buccolingual spasm, and diaphoresis. In all three
of these patients, the symptoms resolved rapidly after the
administration of intravenous diphenhydramine. In the first
patient, a serum assay that used gas chromatography–mass
spectroscopy identified haloperidol and detected no alpra-
zolam. The second patient’s unused pills were identified as
haloperidol. The third patient reported that he had ingested
a pill that was identical in appearance to the Geneva brand
of generic haloperidol, although the person who supplied
the drug to him insisted that the pill in question was generic
alprazolam.
The substitution of haloperidol for the benzodiazepine
diazepam (“street Valium”) was common on the street in the
1970s and 1980s. Both these pills were blue and had a cen-
tral hole.1,2 Physicians today should be aware that haloperi-
dol is being substituted for alprazolam (“street Xanax”),
even though the pills have different shapes and colors.
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